...
首页> 外文期刊>Clinical & translational oncology : >Clinical and prognostic usefulness of serum proteomic profile in hepatic colorectal metastases: A pilot prospective study
【24h】

Clinical and prognostic usefulness of serum proteomic profile in hepatic colorectal metastases: A pilot prospective study

机译:血清蛋白组学在肝大肠转移中的临床和预后价值:一项前瞻性前瞻性研究

获取原文
获取原文并翻译 | 示例

摘要

Purpose: To analyze the use of proteomic profiles to discriminate healthy from patients with colorectal liver metastases (CLM) and to predict neoplastic recurrence after CLM resection. Methods: From April 2005 to October 2008, 70 patients operated for first curative resection of CLM and 60 healthy controls underwent determination of preoperative serum proteomic profile. We performed a preliminary training with patients and controls and obtained a classification system based on these patients' proteomic profiles training. The system was then tested about the ability to predict the colon versus rectum origin, metachronous or synchronous appearance, risk of recurrence after CLM resection and whether a sample was from a control or a CLM patient. Results: Sensitivity, specificity, positive and negative predictive values for detecting CLM patients were 75, 100, 100 and 54.6 %, respectively. Best CLM appearance time identification was 50 % and primary tumor origin identification was 62.5 %. Best classifications of neoplastic recurrence within the first year after CLM resection and during the follow-up period were 47.5 and 45 %, respectively. Larger training sets and prevalence-based training sets led to better classification of patients and characteristics. Conclusion: Proteomic profiles are a promising tool for discriminating CLM patients from healthy patients and for predicting neoplastic recurrence.
机译:目的:分析蛋白质组学谱图的使用,以区分健康人与大肠肝转移(CLM)患者,并预测CLM切除后的肿瘤复发。方法:2005年4月至2008年10月,对70例行CLM根治性切除术的患者和60例健康对照者进行术前血清蛋白质组学测定。我们对患者和对照进行了初步培训,并基于这些患者的蛋白质组学概况培训获得了分类系统。然后测试该系统的预测结肠与直肠起源,异时或同步外观,CLM切除后复发风险以及样本来自对照还是CLM患者的能力。结果:检测CLM患者的敏感性,特异性,阳性和阴性预测值分别为75%,100%,100%和54.6%。最佳CLM出现时间鉴定为50%,原发肿瘤起源鉴定为62.5%。在CLM切除后的第一年内和随访期间,最佳的肿瘤复发分类分别为47.5%和45%。更大的训练集和基于患病率的训练集可以更好地分类患者和特征。结论:蛋白质组学谱图是区分CLM患者和健康患者并预测肿瘤复发的有前途的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号